Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

Vaccine
Darron R BrownKathrin U Jansen

Abstract

A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was given at 0, 2 and 6 months. HPV16 infection was defined by positive polymerase chain reaction (PCR) results following vaccination. The incidence of HPV infection was observed to be 0 cases per 100 person-years at risk in the vaccine group, and 5 cases per 100 person-years at risk in the control group. These results support the institution of larger efficacy trials for HPV L1 VLP vaccines.

References

Sep 20, 1995·Journal of the National Cancer Institute·G Y HoS Romney
Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·J A SuzichR Schlegel
Nov 26, 1999·The New England Journal of Medicine·K L WallinJ Dillner
Jun 30, 2001·JAMA : the Journal of the American Medical Association·A B MoscickiJ Palefsky
Nov 22, 2002·The New England Journal of Medicine·Laura A KoutskyUNKNOWN Proof of Principle Study Investigators

❮ Previous
Next ❯

Citations

Sep 23, 2006·Nature Reviews. Cancer·Richard Roden, T-C Wu
Jan 11, 2007·Clinical Medicine & Research·Michelle M Lipke
Jul 14, 2007·Infectious Agents and Cancer·Ralph P InsingaEliav Barr
Mar 1, 2008·Biologics : Targets & Therapy·Archana MonieT-C Wu
Jul 10, 2010·International Journal of Environmental Research and Public Health·Heidi Muller, Chris Bauch
Apr 2, 2011·BMC Public Health·Vernon J LeeMei Yin Tok
Nov 17, 2007·The Journal of Infectious Diseases·Susanne Krüger KjaerMari Nygård
Jan 27, 2009·Archives of Virology·Ramon PereiraEdward P Rybicki
Oct 20, 2006·Expert Opinion on Biological Therapy·Engy Hanna, Gloria Bachmann
Oct 27, 2004·Expert Opinion on Biological Therapy·Kathrin U Jansen
Mar 4, 2010·Vaccine·Giuseppe La TorreWalter Ricciardi
Oct 27, 2009·Archives of Medical Research·Lutz Gissmann
Apr 7, 2009·Annals of Epidemiology·Laura Koutsky
Feb 19, 2008·The Journal of Pediatrics·Amanda F Dempsey, Gary L Freed
Dec 31, 2005·European Journal of Immunology·Alfonso J García-PiñeresLigia A Pinto
Sep 5, 2006·Vaccine·Stephen InglisScott Koenig
Sep 5, 2006·Vaccine·Laura A Koutsky, Diane M Harper
Dec 27, 2005·The Lancet Infectious Diseases·Jeffrey M Partridge, Laura A Koutsky
Aug 13, 2005·Mathematical Biosciences·Elamin H Elbasha, Alison P Galvani
Jun 6, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Elamin H ElbashaEliav Barr
May 4, 2005·Memórias do Instituto Oswaldo Cruz·Alcina Frederica NicolMaria da Gloria Bonecini-Almeida
Jul 20, 2006·The Annals of Pharmacotherapy·Mia R Schmiedeskamp, Denise R Kockler
Apr 28, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ming-Shien YenCheng-Yang Chou
Apr 7, 2005·Nature Medicine·Barry C Buckland
Jun 29, 2007·Clinical and Vaccine Immunology : CVI·Alfonso García-PiñeresLigia A Pinto
Dec 13, 2019·The Journal of International Medical Research·Sudong LiuZhixiong Zhong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.